Integra Lifesciences Holdings (IART) Gains from Investment Securities (2014 - 2026)

Integra Lifesciences Holdings (IART) has 13 years of Gains from Investment Securities data on file, last reported at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 698.15% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$22.5 million (down 250.44% YoY), and the FY2025 full-year result was -$21.3 million, down 268.31% from the prior year.
• Gains from Investment Securities grew to -$1.3 million in Q1 2026, from -$6.7 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $4.7 million in Q1 2023 to a low of -$14.4 million in Q3 2025.
• A 5-year average of -$2.1 million and a median of -$765000.0 in 2022 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities slumped 8505.03% in 2022 and surged 714.25% in 2023, its largest moves.
• Tracing IART's Gains from Investment Securities over 5 years: stood at -$823000.0 in 2022, then surged by 660.15% to $4.6 million in 2023, then sank by 218.7% to -$5.5 million in 2024, then decreased by 22.17% to -$6.7 million in 2025, then soared by 80.66% to -$1.3 million in 2026.
• Business Quant data shows IART's Gains from Investment Securities at -$1.3 million in Q1 2026, -$6.7 million in Q4 2025, and -$14.4 million in Q3 2025.